Patient safety alert – Resources to support the safety of girls and women who are being treated with valproate

Patient safety alert – Resources to support the safety of girls and women who are being treated with valproate

April 7, 2017

The Medicines and Healthcare products Regulatory Agency (MHRA) and NHS Improvement have published a patient safety alert relating to girls and women who are being treated with valproate.

The actions in the alert ask all organisations providing NHS funded-care where valproate is prescribed or dispensed to identify girls and women who are being treated with valproate, and ensure the MHRA resources are used to support them to make informed choices. Action should be taken as soon as possible and completed by 6th October 2017.

The MHRA has also published a guidance document on using the valproate toolkit (previously published by MHRA) for those prescribing and dispensing valproate and also includes specific action points for pharmacists.

Contractors are reminded that there is a patient safety report quality criterion in the Quality Payments Scheme, and in order to claim for that criterion, the following must be met:

Written safety report at premises level available for inspection at review point, covering analysis of incidents and incident patterns (taken from an ongoing log), evidence of sharing learning locally and nationally, and actions taken in response to national patient safety alerts.



Posted in:


More Latest News >